RAG
ADMA icon

RIA Advisory Group’s ADMA Biologics ADMA Stock Holding History

RIA Advisory Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.8K Buy
11,332
+476
+4% +$4.34K 0.02% 153
2026
Q1 		$97.8K Buy
+10,856
New +$171K 0.02% 143

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RIA Advisory Group's ADMA Position: Q2 2026 in Review

RIA Advisory Group increased its ADMA Biologics (ADMA) stake by 4.4% in Q2 2026, buying an estimated $4.34K and bringing the position to 11,332 shares worth $94.8K. The position accounts for 0.02% of the portfolio, ranked #153.

RIA Advisory Group first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $97.8K in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • RIA Advisory Group held 11,332 shares of ADMA Biologics worth $94.8K as of Q2 2026.
  • RIA Advisory Group bought 476 ADMA Biologics shares in Q2 2026, an estimated $4.34K.
  • ADMA Biologics made up 0.02% of RIA Advisory Group's portfolio in Q2 2026, its #153 holding.
  • RIA Advisory Group first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • RIA Advisory Group's ADMA Biologics position peaked at $97.8K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on RIA Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.